Arbutus Biopharma Seeks a Share of Moderna’s Revenues Should its COVID-19 Vaccine (mRNA-1273) be Approved: Patent Dispute

Moderna, the maker of mRNA-1273, one of the leading COVID-19 experimental vaccine candidates, has attracted enormous attention from investors, society, and the press, not to mention from health authorities and governments around the world. Now they have new attention:...

Pin It on Pinterest